Efficacy and Safety of BGG492 in the Treatment of Migraine

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy and safety of BGG492 used to treat migraine pain.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Sumatriptan

Criteria

Inclusion Criteria:

• Diagnosis of moderate to severe migraine for at least 1 year

• At least 1 migraine episode, but not more 15 migraine days per month

• Past use of triptans

• Migraine onset before 50 years of age

Exclusion Criteria:

• Diagnosis of basilar, ophthalmoplegic or hemiplegic migraine.

• More than 6 non-migraine headaches per month

• Patients receiving migraine prophylaxis treatment

• Patients receiving regular treatment with psychoactive drugs

• Smokers

• Patients with a very high or low body weight Other protocol-defined inclusion/exclusion criteria may apply